Histone deacetylase enzymes (HDACs) are emerging cancer drug targets. They regulate gene expression by removing acetyl groups from lysine residues in histone tails, resulting in chromatin condensation. The enzymatic activity of most class I HDACs requires recruitment into multi-subunit co-repressor complexes, which are in turn recruited to chromatin by repressive transcription factors. Here we report the structure of a complex between an HDAC and a co-repressor, namely, human HDAC3 with the deacetylase activation domain (DAD) from the human SMRT co-repressor (also known as NCOR2). The structure reveals two remarkable features. First, the SMRT-DAD undergoes a large structural rearrangement on forming the complex. Second, there is an essential inositol tetraphosphate molecule-D-myo-inositol-(1,4,5,6)-tetrakisphosphate (Ins(1,4,5,6)P 4 )-acting as an 'intermolecular glue' between the two proteins. Assembly of the complex is clearly dependent on the Ins(1,4,5,6)P 4 , which may act as a regulator-potentially explaining why inositol phosphates and their kinases have been found to act as transcriptional regulators. This mechanism for the activation of HDAC3 appears to be conserved in class I HDACs from yeast to humans, and opens the way to novel therapeutic opportunities.
Histone deacetylase enzymes (HDACs) are emerging cancer drug targets. They regulate gene expression by removing acetyl groups from lysine residues in histone tails, resulting in chromatin condensation. The enzymatic activity of most class I HDACs requires recruitment into multi-subunit co-repressor complexes, which are in turn recruited to chromatin by repressive transcription factors. Here we report the structure of a complex between an HDAC and a co-repressor, namely, human HDAC3 with the deacetylase activation domain (DAD) from the human SMRT co-repressor (also known as NCOR2). The structure reveals two remarkable features. First, the SMRT-DAD undergoes a large structural rearrangement on forming the complex. Second, there is an essential inositol tetraphosphate molecule-D-myo-inositol- (1, 4, 5, 6 )-tetrakisphosphate (Ins(1,4,5,6)P 4 )-acting as an 'intermolecular glue' between the two proteins. Assembly of the complex is clearly dependent on the Ins (1, 4, 5, 6 )P 4 , which may act as a regulator-potentially explaining why inositol phosphates and their kinases have been found to act as transcriptional regulators. This mechanism for the activation of HDAC3 appears to be conserved in class I HDACs from yeast to humans, and opens the way to novel therapeutic opportunities.
The acetylation of lysine residues in the tails of histone proteins plays an important role in the regulation of gene expression in eukaryotic cells 1, 2 . The level of lysine acetylation is controlled through the opposing actions of histone acetyl transferases (HATs) and HDACs. Although chromatin is the best understood substrate for these enzymes, lysine acetylation is emerging as a general regulatory mechanism in a diverse array of cellular processes 3 .
There are four classes of HDACs in mammalian cells (reviewed in ref. 4) . Class I HDACs are zinc-dependent enzymes, and include HDAC1, 2, 3 and 8. Of these, only HDAC8 is a fully functional enzyme in isolation 5, 6 . HDAC1, 2 and 3 require recruitment into large multi-subunit co-repressor complexes for maximal activity 7-12 . These co-repressor complexes bring about the repression of gene expression when recruited to repressive transcription factors, but also contribute to the 'resetting' of chromatin after rounds of transcriptional activation [13] [14] [15] [16] .
In recent years, HDACs have become important targets for the treatment of a number of cancers 17 . Cancer cell lines treated with HDAC inhibitors undergo terminal differentiation, growth arrest and/or apoptosis. Several HDAC inhibitors are at various stages in clinical trials, and two drugs, vorinostat and romidepsin, have been approved for the treatment of cutaneous T-cell lymphomas 18 .
HDAC1 and 2 are found in three co-repressor complexes: NuRD 7,19 , CoREST 20,21 and Sin3A 22, 23 . In contrast, HDAC3 appears to be uniquely recruited to the SMRT complex (or to the homologous NCoR complex) where it interacts with a conserved DAD within SMRT or NCoR 8, 10, 12, [24] [25] [26] . The DAD both recruits and activates HDAC3 [10] [11] [12] . Recruitment of HDAC3 to the DAD is essential for repression by certain nuclear receptors and for the maintenance of normal circadian physiology [27] [28] [29] . It has been proposed that the assembly of the HDAC3 and SMRT-DAD requires a chaperone complex, because when these proteins are expressed in bacteria they do not form a complex 30 .
The DAD contains an extended SANT-like domain with an aminoterminal DAD-specific motif. Deletion of this motif results in both loss of binding and failure to activate HDAC3 11 .We have previously reported the structure of the isolated DAD from SMRT 31 . This revealed that part of the DAD-specific motif forms an extra helix that is folded against the three helices of the SANT domain to form a fourhelix bundle. The N-terminal portion of the DAD-specific motif is unstructured in solution 31 .
Here we report the structure of HDAC3 in complex with SMRT-DAD. This structure not only reveals the specificity and mechanism through which SMRT-DAD recruits and activates HDAC3, but also identifies Ins(1,4,5,6)P 4 as a key component of the complex that has the potential to regulate assembly of HDACs with their co-repressors.
Overall architecture of the complex
As HDAC3 and SMRT-DAD do not form a complex when expressed in bacterial cells, full-length HDAC3 and Flag-tagged SMRT-DAD (amino acids 389-480) were expressed in suspension-grown mammalian HEK293 cells. The complex remained tightly associated during a three-step purification, including size exclusion chromatography ( Supplementary Fig. 1 ). Interestingly, at salt concentrations higher than 50 mM, the complex dissociated and the HDAC3 predominately took the form of aggregate or oligomers ( Supplementary  Fig. 2 ). Such oligomerization of HDAC3 has also been reported by others 32 . During crystallization, the HDAC3 tail is proteolysed but HDAC3 remains bound to SMRT-DAD and retains deacetylase activity ( Supplementary Fig. 3 ). Small crystals (15 mm; Supplementary Fig. 1 ) diffracted to 2 Å and the structure was solved by molecular replacement with an HDAC8 structure 33 . Model building and refinement yielded an excellent map to 2.1 Å resolution with clear density for both HDAC3 and SMRT-DAD ( Supplementary Fig. 1 ).
Overall, the HDAC3 structure is similar to the previously determined class I HDAC structures of HDAC8 34 and HDAC2 35 , and consists of an eight-stranded parallel b-sheet surrounded by a number of a-helices. The active site lies at the base of a tunnel leading from the surface of the protein. A solvent-exposed tyrosine residue is located on the surface of the enzyme immediately adjacent to the active site tunnel. This tyrosine is unique to HDAC3, and it seems that this residue might interact with the substrate and possibly contribute to substrate specificity ( Supplementary Fig. 4 ).
Structural rearrangement of SMRT-DAD
On forming a complex with HDAC3, the N-terminal helix of the DAD undergoes a major structural rearrangement (from that seen in the NMR structure), such that it no longer forms part of the core structure, but lies along the surface of HDAC3, making extensive intermolecular interactions ( Fig. 1a, b ). Along with a further extended region, this DAD-specific motif buries a surface of 1,178 Å 2 . The remaining three-helix bundle resembles a canonical SANT domain, and buries a further 1,160 Å 2 at the interface with HDAC3.
The SMRT-DAD interacts with the N-terminal region of HDAC3 (residues 9-49) that forms helix H1, loop L2, helix H2 and strand S2. This region differs between HDAC8 and HDAC3. Indeed, in HDAC3, helix H1 is distorted and can only be considered to be a pseudo-helix. These differences may explain why HDAC8 is active in the absence of an interacting co-repressor.
An essential role for Ins (1, 4, 5, 6) 
At the earliest stages of refinement, the electron density difference map revealed a well-ordered small molecule bound at the interface between HDAC3 and the DAD (Fig. 2a ). The electron density was sufficiently well defined that the small molecule could be readily identified as inositol tetraphosphate. During further refinement, it could be unambiguously assigned as D-myo-inositol-1,4,5,6tetrakisphosphate (based on the axial orientation of the hydroxyl group on carbon 2), referred to here as Ins(1,4,5,6)P 4 (Fig. 2b) .
The Ins(1,4,5,6)P 4 molecule is sandwiched between HDAC3 and the DAD, in a highly basic pocket, making extensive contacts to both proteins, burying a surface of 407 Å 2 (Fig. 2c, d ). HDAC3 and SMRT-DAD each contribute five hydrogen bonds and salt bridges to the Ins(1,4,5,6)P 4 (His 17, Gly 21, Lys 25, Arg 265, Arg 301 and Lys 449, Tyr 470, Tyr 471, Lys 474 and Lys 475, respectively) ( Fig. 2e ).
It is notable that the Ins(1,4,5,6)P 4 is sufficiently tightly bound to the complex that it is retained through the entire purification process. It is also striking that the binding is highly specific for Ins(1,4,5,6)P 4 , as the electron density shows that the ligand is uniquely Ins(1,4,5,6)P 4 rather than a mixture of inositol phosphates.
A careful examination of the structure suggests that Ins(1,4,5,6)P 4 binding is an essential requirement for the interaction between SMRT and HDAC3, acting as a 'intermolecular glue' that cements the complex together. If the Ins(1,4,5,6)P 4 ligand were not present, then the many basic residues on either side of the binding cleft would probably prevent interaction through charge repulsion. Indeed, at the base of the cleft, the f-nitrogen atoms of SMRT Lys 449 and of HDAC3 Lys 25 are just 4.4 Å from each other. Consequently, the assembly of the threeway SMRT-HDAC3-Ins(1,4,5,6)P 4 complex appears to be mutually interdependent, such that both SMRT-DAD and Ins(1,4,5,6)P 4 are required for activation of the HDAC3 enzymatic functionality.
These conclusions are supported by our previous mutagenesis study of SMRT-DAD, in which we looked at the effect of mutations on both the interaction with, and the deacetylase activity of, HDAC3. All mutations that failed to activate HDAC3 also abolished, or significantly impaired, interaction. These include mutations of Lys 449, Tyr 470 and Tyr 471, which play a key role in binding Ins(1,4,5,6)P 4 (ref. 31 ). The requirement for Ins(1,4,5,6)P 4 to enable complex formation may contribute to the explanation as to why recombinant HDAC3 and SMRT-DAD expressed in bacteria fail to interact, as bacteria probably do not contain sufficient Ins (1, 4, 5, 6 )P 4 to support complex formation.
Having discovered that Ins(1,4,5,6)P 4 plays a key role in HDAC3 activation, we asked whether inositol phosphates might contribute to the assembly and activation of other class I HDAC complexes. Significantly, the residues that mediate interaction with Ins(1,4,5,6)P 4 and the SANT domain from SMRT are conserved in both HDAC1 and 2, but not in HDAC8 ( Fig. 3a) , fitting with the observation that only HDAC8 is fully active in isolation.
Similarly, the co-repressor partners for HDAC1 and 2 (that is, MTA1, 2 and 3 and CoREST1, 2 and 3) contain SANT domains that are analogous to SMRT-DAD. The key Ins(1,4,5,6)P 4 binding residues are almost entirely conserved (Fig. 3b ). It is likely that the specificity for the particular HDAC is conferred by the region N-terminal to the SANT domain: that is, the DAD specific motif in SMRT/NCoR and the ELM2 domains in the MTA and CoREST proteins.
Taken together, this suggests that inositol phosphate activation of class I HDACs is a general mechanism and, given that the key residues are also found in the yeast HDAC, Rpd3, and the Snt1 co-repressor, it would appear that this mechanism is also evolutionarily conserved.
Mechanism of activation of HDAC3
The HDAC3-SMRT-DAD structure provides insight into the mechanism through which the DAD and Ins(1,4,5,6)P 4 contribute to the activation of HDAC3. In the crystal, the active site of HDAC3 resembles a product complex (Fig. 4a, b ). An acetate molecule (present during purification) is bound at the active site, making hydrogen bonds to the catalytic zinc and side chains of Ty 298 and His 134. Furthermore, a methionine side chain (from an adjacent SMRT-DAD in the crystal lattice) is bound in the active site tunnel, mimicking a lysine residue. 
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The binding surfaces for DAD and Ins(1,4,5,6)P 4 are located to one side of the HDAC3 active site, involving pseudo helix H1 and loops L1 and L6 (Fig. 4a-c) . We propose that changes in both conformation and dynamics occur when DAD and Ins(1,4,5,6)P 4 bind to HDAC3, and that these facilitate substrate access to the active site, resulting in enhanced enzyme activity.
There is a key interaction between Ins(1,4,5,6)P 4 and Arg 265 in loop L6 (coloured orange in Fig. 4b ). This loop seems to be very important for access to the active site, because Leu 266 forms one wall of the active site tunnel, and in the absence of the Ins(1,4,5,6)P 4 this loop is likely to be relatively mobile.
Comparison of the HDAC3 structure with that of HDAC8, which does not require activation by complex formation, reveals that HDAC8 differs significantly in the region where HDAC3 interacts with SMRT-DAD and Ins(1,4,5,6)P 4 (Fig. 4d ). In HDAC8, the equivalent helix to pseudo helix H1 in HDAC3 has a regular helical structure, loop L1 is two amino acids shorter and loop L6 contains a proline residue that partly orientates the loop away from the active site ( Fig. 4d ). We suggest that together these differences give substrate better access to that active site of HDAC8 than would be possible in the uncomplexed HDAC3. The pattern of crystallographic temperature factors for the various structures supports this interpretation ( Supplementary Fig. 5 ).
To test the importance of Arg 265 as well as loops L1 and L6, we co-expressed mutant HDAC3 constructs with SMRT-DAD in mammalian cells. Strikingly, all the designed mutations resulted not only in total loss of deacetylase activity (Fig. 5a ) but also abolished interaction with SMRT-DAD (Fig. 5b) . These findings support our interpretation of the importance of these residues in the activation of HDAC3.
To support the conclusions that Ins(1,4,5,6)P 4 is essential for HDAC3 activity and to test the specificity for Ins(1,4,5,6)P 4 , we sought to establish an in vitro reconstitution assay. We expressed 
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and purified HDAC3, Flag-tagged at the carboxy terminus, from mammalian cells and incubated the anti-Flag resin with bacterially expressed SMRT-DAD and various concentrations of Ins(1,4,5,6)P 4 , Ins(1,4,5)P 3 and Ins(1,2,3,4,5,6)P 6 (Fig. 5c ). HDAC activity was very sensitive to inositol phosphate concentration and higher concentrations do not support reconstitution. This can be explained through high levels of free inositol phosphate competing with complex formation. This is analogous to moderate monovalent salt concentrations causing complex dissociation during purification ( Supplementary  Fig. 2) . A similar pattern of activation was seen using both Ins(1,4,5)P 3 and Ins(1,2,3,4,5,6)P 6 , but in both cases a tenfold higher concentration was required to achieve a similar level of HDAC activity to that seen with Ins(1,4,5,6)P 4 . This supports the interpretation that Ins(1,4,5,6)P 4 is the physiologically relevant assembly partner.
Does Ins(1,4,5,6)P 4 regulate HDACs?
The finding that Ins(1,4,5,6)P 4 is essential for the assembly of class 1 HDAC repression complexes raises the question as to whether it is a signalling molecule with a role in regulating complex assembly, or if it is simply an essential structural cofactor.
The fact that Ins(1,4,5,6)P 4 remained bound during purification would seem to suggest that it is a structural cofactor. However, to retain an intact complex it was necessary to use low ionic strength buffers. At physiological ionic strengths, the Ins(1,4,5,6)P 4 is likely to dissociate readily and thus could regulate complex assembly.
Importantly, several studies have previously implicated Ins (1, 4, 5, 6 )P 4 as a regulator of gene expression and chromatin remodelling-although no molecular mechanism was identified. Yeast Arg 82 is a transcriptional regulator of genes involved in arginine metabolism. It has been shown 36 that Arg 82 is an inositol phosphate kinase that converts Ins(1,4,5)P 3 to Ins(1,4,5,6)P 4 and that kinase activity is required for its role in transcriptional regulation (Fig. 5d ). Several further studies have supported the importance of Arg 82 kinase activity in transcriptional regulation and chromatin remodelling [37] [38] [39] , together suggesting that Ins (1, 4, 5, 6 )P 4 has an important regulatory role in yeast.
IPMK, the mammalian homologue of Arg 82, has been reported to phosphorylate Ins(1,4,5)P 3 to form Ins(1,3,4,5,6)P 4 
and then
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Ins(1,3,4,5,6)P 5 (refs 40, 41) . Consequently, in mammalian cells, a phosphatase is required to generate Ins(1,4,5,6)P 4 . The most likely enzyme is the well-known tumour suppressor gene PTEN 42, 43 , which is known to be active in the nucleus and to play a role in chromosome stability (reviewed in ref. 44) . It is tempting to speculate that loss of HDAC complex function might be one of the routes through which PTEN mutations contribute to oncogenesis. A final important question is whether the levels of Ins(1,4,5,6)P 4 are regulated in the cell. This is not easy to establish, as regulation could be temporally and/or spatially compartmentalized. However there is some evidence that both PTEN and InsP 4 levels change with progression through the cell cycle 45 . It is also possible that changing levels of Ins(1,4,5,6)P 4 may contribute to the circadian regulation of HDAC3 activity 46 . Further research will be needed to clarify these important questions.
Discussion
We present the structure of a histone deacetylase in complex with its activating co-repressor. The structure reveals a striking structural rearrangement of the co-repressor and an unexpected inositol tetraphosphate molecule (Ins(1,4,5,6)P 4 ) acting as an 'intermolecular glue', contributing to the stabilization and activation of HDAC3.
Sequence conservation suggests that Ins(1,4,5,6)P 4 plays a key role in co-repressor assembly and activation of class I HDACs from yeast to humans and is likely to act as a regulator of HDAC complex assembly. Although it remains to be established how the availability of Ins(1,4,5,6)P 4 might be controlled, the requirement of Ins(1,4,5,6)P 4 for co-repressor HDAC assembly presents novel opportunities for therapeutic intervention that may complement existing HDAC inhibitors. It may be possible to develop molecules that target the Ins(1,4,5,6)P 4 binding site itself, but it may also be possible to target the enzymes responsible for Ins(1,4,5,6)P 4 synthesis.
METHODS SUMMARY
HDAC3 and Flag-tagged SMRT-DAD (residues 389-480) were expressed using transient transfection in suspension grown HEK293F cells. The HDAC3-SMRT-DAD complex was purified by Flag affinity chromatography, followed by TEV protease cleavage and size exclusion chromatography. Crystals of the HDAC3-DAD complex were grown by sitting drop vapour diffusion with a 10% propan-2ol precipitant. The structure was determined by molecular replacement based on HDAC8 (PDB code 3EW8). Ligands, including Ins(1,4,5,6)P 4 , zinc, potassium, acetate and glycerol were added during the refinement process.
